Promab Biotechnologies

Promab Biotechnologies is a long-established, privately-held biotech service provider offering a unique, integrated suite of capabilities across three high-growth technology areas: custom antibody generation, CAR-T/NK cell therapy development, and mRNA-LNP delivery platforms. The company operates as a CRO/CDMO, enabling its clients—likely ranging from academic institutions to biopharma companies—to outsource complex R&D and manufacturing steps. With a track record of over 5,000 antibodies generated and 500+ CAR-T projects, Promab has supported programs into Phase 2 clinical trials, positioning itself as a key enabler in the rapidly evolving cell and gene therapy space. Its business model is based on providing fee-for-service and collaborative development work rather than developing its own proprietary drug pipeline.

Integrated service platforms for custom antibody engineering (discovery, humanization, production), CAR-T/NK cell therapy development (design, lentivirus production, cell manufacturing), and mRNA-Lipid Nanoparticle (LNP) formulation and gene delivery. Supporting services include protein expression, stable cell line development, and cell-based assays.

Promab competes with a broad range of players, including large global CDMOs (e.g., Lonza, Catalent), specialized antibody service CROs, and niche cell therapy developers offering CRO services. Its key differentiator is the integrated offering of antibody, CAR-T, and mRNA-LNP services under one roof, which is less common among competitors.